News | Interventional Radiology | February 04, 2020

Interventional Radiologists Increasingly Using Ablation to Treat Kidney Cancer

New SIR position statement and quality documents highlight effective use of nonsurgical ablation to treat kidney cancer in selected patients

New SIR position statement and quality documents highlight interventional radiology effective use of nonsurgical ablation to treat kidney cancer in selected patients

February 4, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the Society of Interventional Radiology’s (SIR) first-ever position statement on the role of percutaneous ablation in the treatment of renal cell carcinoma. The position statement was published with an accompanying quality improvement document, which establishes performance thresholds for patient safety for interventional radiology (IR) groups who wish to develop a renal ablation practice.

The position statement and quality improvement document, published in the February 2020 issue of SIR’s flagship Journal of Vascular and Interventional Radiology (JVIR), were written by a multidisciplinary group of experts, including interventional radiologists and urologists.[1]

The authors recommend thermal percutaneous ablation (PA) for kidney cancer patients with small renal tumors calling it “a safe and effective treatment with less complications than nephrectomy (surgery) and acceptable long-term oncological and survival outcomes.”  Unlike current existing guidelines, the position statement offers recommendations on the consideration of treatment over active surveillance and discusses the incorporation of ablation for appropriate patients with T1b disease. 

“Interventional radiologists are critical members of the multidisciplinary team caring for patients with kidney cancer. They have an important role, not only in the diagnosis of cancer but in its definitive treatment,” said SIR President Laura Findeiss, M.D., FSIR. “An image-guided biopsy by an IR can confirm a diagnosis of cancer and the interventional radiologist can be a game-changer as a partner physician on the cancer care team, expanding access to the complete range of therapeutic options, tailored to the individual patient.”
The position statement’s authors deemed radiofrequency (RF) ablation, cryoablation, and microwave ablation “appropriate modalities” noting that the “method of ablation should be left to the discretion of the operating physician.”

According to the statement, PA may have a potential beneficial role to play in the treatment of high-risk patients with more advanced disease who are not candidates for surgery, but further research is necessary. Read the full position statement and quality improvement guidelines on jvir.org.

Renal cell carcinoma (RCC) is the most common type of kidney cancer and an estimated 73,820 new cases of kidney cancer will be diagnosed in the United States in 2019, resulting in 14,770 new deaths. 

For more information: sirweb.org

 

Reference:

1. Christopher S. Morris, Christopher S. Morris, Christopher S. Morris, et al. Society of Interventional Radiology Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma. Journal of Vascular and Interventional Radiology (JVIR). February 2020Volume 31, Issue 2, Pages 189–194.e3

 

 

 

Related Content

News | Ablation Systems

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News | Ablation Systems

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
Subscribe Now